U.S., Oct. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07899840) titled 'Establishment of a Novel Flow Cytometric Diagnostic Assay to Effectively Evaluate Immune Reconstitution After Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia' on Oct. 20.

Brief Summary: Primary Objective

To assess immune reconstitution during the first 18 months following hematopoietic stem cell transplantation (HSCT) for acute lymphoblastic leukemia (ALL), with a particular focus on the T-cell compartment (thymic regeneration and surrogate markers of cytotoxic function), using a dedicated panel developed within the EuroFlow consortium.

Secondary Objectives

To assess the impact of donor and recipient char...